Frequent detection of 'azole' resistant Candida species among late presenting AIDS patients in northwest Ethiopia

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Mulu, Andargachew ^a,b   Kassu, Afework ^a   Anagaw, Belay ^a   Moges, Beyene ^a   Gelaw, Aschalew ^a   Alemayehu, Martha ^a   Belyhun, Yeshambel ^a   Biadglegne, Fantahun ^a   Hurissa, Zewdu ^a   Moges, Feleke ^a   Isogai, Emiko ^c  

^a UNIVERSITY OF GONDAR   (Ethiopia)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Candida species diversity; In vitro susceptibility; Late presenters; Northwest Ethiopia

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; PYRROLE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AIDS PATIENT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; COLONY FORMING UNIT; CROSS RESISTANCE; CULTURE MEDIUM; DRUG EXPOSURE; ETHIOPIA; FEMALE; FUNGAL COLONIZATION; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MICROBIAL DIVERSITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; MOUTH HYGIENE; NONHUMAN; OROPHARYNX CANDIDIASIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CANDIDIASIS, ORAL; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; DRUG RESISTANCE, MULTIPLE, FUNGAL; ETHIOPIA; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84873699825     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-82     Document Type: Article

References (41)

1. Samaranayake LP, Fidel PL, Naglik JR. Fungal infections associated with HIV infection. Oral Dis 2002, 23(Suppl 2):151-160.
2. Diro E, Feleke Y, Guteta S, Fekade D, Neway M. Assessment of Risk Behaviours and Factors Associated with Oral and Peri-oral Lesions in Adult HIV Patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. Ethiop J Health Dev 2008, 22:180-186.
3. Campo J, Del Romero J, Castilla J, Garcia S, Rodriguez C, Bascones A. Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. J Oral Pathol Med 2002, 31:5-10. 10.1034/j.1600-0714.2002.310102.x, 11896816.
4. Mikx FHM, Verweij PE, van der Ven AJAM. Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health 2006, 6:12. 10.1186/1472-6831-6-12, 1559688, 16916469.
5. WHO New report on global problem of oral diseases 2004, Geneva, http://www.who.int/mediacentre/news/releases/2004/pr15/en/, WHO.
6. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004, 10(Suppl 1):1-10.
7. Colombo AL, Da Matta D, De Almeida LP, Rosas R. Fluconazole susceptibility of Brazilian Candida isolates assessed by a disk diffusion method. J Infect Dis 2002, 6:118-123.
8. Hamza O, Matee M, Moshi M. Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol 2008, 8:135. 10.1186/1471-2180-8-135, 2518160, 18694525.
9. Mulu A, Diro E, Tekleselassie H. Effect of Ethiopian multiflora honey on fluconazole-resistant Candida species isolated from the oral cavity of AIDS patients. Int J STD AIDS 2010, 21:1-5.
10. Müller FMC, Weig M, Peter J, Walsh TJ. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother 2000, 46:338-341. 10.1093/jac/46.2.338, 10933673.
11. Pelletier R, Peter J, Antin C, Gonzalez C, Wood L, Walsh TJ. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: In vitro and clinical correlations. J Clin Microbiol 2000, 38:1563-1568. 86490, 10747144.
12. Wabe N, Hussein J, Suleman S, Abdella K. In vitro antifungal susceptibility of Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus in Ethiopia. J Exp Integr Med 2011, 1:265-271.
13. Woldeamanuel Y, Abate D. Characterization of C. albicans isolates from the oral cavity of HIV positive patients. Ethiop Med J 1998, 36:235-243.
14. Redding SW, Kirpatrick WR, Dib O, Fothergill AW, Rinaldi MG, Patterson TF. The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients. Spec Care Dentist 2000, 20:178-181. 10.1111/j.1754-4505.2000.tb00015.x, 11203894.
15. Guidelines for management of opportunistic infections and antiretroviral treatment in adolescents and adults in Ethiopia 2007, Addis Ababa Ethiopia: Federal HIV/AIDS Prevention and Control Office Federal Ministry of Health.
16. Standard treatment guideline 2004, Addis Ababa: Drug Administration and Control authority, Ministry of Health.
17. Isogai H, Mulu A, Diro E. Identification of Candida species from Human Immunodeficiency Virus-infected Patients in Ethiopia by Combination of CHROMagar, Tobacco agar and PCR of Amplified Internally Transcribed rRNA Spacer Region. J Appl Res 2010, 10:1-7.
18. Epstein JB, Pearsall NN, Truelove EL. Quantitative relationship between Candida albicans and the clinical status of human subjects. J Clin Microbiol 1980, 12:475-476. 273612, 7012183.
19. CLSI Reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd ed. M27-A3 2008, Wayne, PA: Clinical and Laboratory Standards Institute, CLSI.
20. Moore JE, MC Mullan R. Comparison of media for optimal recovery of Candida albicans and Candida glabrata from blood culture. Irish Med J 2003, 172:60-62.
21. Brito GN, Inocêncio AC, Querido SM. In vitro antifungal susceptibility of Candida spp. oral isolates from HIV positive patients and control individuals. Braz Oral Res 2010, 25:28-33.
22. Blignaut E, Botes M, Nieman H. The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients. SADJ 1999, 54:605-608.
23. Blignaut E, Messer S, Hollis RJ, Pfaller MA. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infec Dis 2002, 44:169-174.
24. Blignaut E. Oral candidiasis and oral yeast carriage among institutionalized South African paediatric HIV/AIDS patients. Mycopathologia 2007, 163:67-73. 10.1007/s11046-006-0087-9, 17295100.
25. Cartledge JD, Middle J, Gazzard BG. Non-albicans oral candidosis in HIV-positive patients. J Antimicrob Chemother 1999, 43:419-422. 10.1093/jac/43.3.419, 10223601.
26. Paula CR, Sampaio MC, Birman EG, Siqueira AM. Oral yeasts in patients with cancer of the mouth, before and during radiotherapy. Mycopathologia 1990, 112:119-124. 10.1007/BF00436507, 2293033.
27. Cannon RD, Lamping E, Holmes AR, Niimi K, Tanabe K, Niimi M, Monk BC. Candida albicans drug resistance-another way to cope with stress. Microbiology 2007, 153:3211-3217. 10.1099/mic.0.2007/010405-0, 17906120.
28. Satana D, Gonca Erkose Genc, Erturan Z. The antifungal susceptibilities of oral Candida spp isolates from HIV-infected patients. Afr J Microbiol Res 2010, 4:466-470.
29. Mulu A, Moges F, Tessema B, Kassu A. Pattern and multiple drug resistance of bacterial pathogens isolated from wound infection at University of Gondar Teaching Hospital, Northwest Ethiopia. Ethiop Med J 2006, 44:125-131.
30. Redding S, Smith J, Farinacci G, Rinaldi M, Fothergill A, Rhine-Chalberg J, Pfaller M. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994, 18:240-242. 10.1093/clinids/18.2.240, 8161633.
31. Hartung de Capriles C, Mata-Essayag S, Pérez C, Colella MT, Roselló A, Olaizola C, Abate SM. Detection of Candida dubliniensis in Venezuela. Mycopathologia 2005, 160:227-234. 10.1007/s11046-005-6873-y, 16205971.
32. Goldman M, Cloud GA, Smedema M, LeMonte A, Connolly P, McKinsey DS, Kauffman CA, Moskovitz B, Wheat LJ. Does long-term itraconazole prophylaxis result in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection?. Antimicrob Agents Chemother 2000, 44:1585-1587. 10.1128/AAC.44.6.1585-1587.2000, 89917, 10817713.
33. Enwuru CA, Ogunledun A, Idika N, Enwuru NV, Ogbonna F, Aniedobe M. Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. Afr Health Sci 2008, 8:142-148. 2583271, 19357740.
34. Pfaller MA, Messer SA, Hollis RJ, Jones JN. Trends in Species distribution and Susceptibility to fluconazole among blood Stream Isolates of Candida species in the United States. Diagn Microbiol Infect Dis 1999, 33:217-222. 10.1016/S0732-8893(98)00160-6, 10212747.
35. Lyon JP, Moreira LM, Cardoso MAG, Saade J, Resende MA. Antifungal susceptibility profile of Candida spp. oral isolates obtained from denture wearers. Braz J Microbiol 2008, 39:668-672.
36. Rautemaa R, Richardson M, Pfaller MA, Perheentupa J, Saxén H. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. Diagn Microbiol Infect Dis 2008, 62:182-185. 10.1016/j.diagmicrobio.2008.05.007, 18597968.
37. Rogers TR. Antifungal drug resistance: limited data, dramatic impact?. Int J Antimicrob Agents 2006, 27(Suppl 1):7-11.
38. Wingeter MA, Guilhermetti E, Shinobu CS, Takaki I, Svidzinski TIE. Identificação microbiológica e sensibilidade in vitro de Candida isoladas da cavidade oral de indivíduos HIV positivos. Rev Soc Bras Med Trop 2007, 40:272-276. 10.1590/S0037-86822007000300004, 17653459.
39. Khan S, Singhal S, Mathur T, Upadhyay DJ, Rattan A. Antifungal susceptibility testing method for resource constrained laboratories. Indian J Med Microbiol 2006, 24:171-176.
40. Manavathu E, Nune U, Kanuri K, Chandrasekar P, Abraham O. Effect of test medium on in vitro susceptibility testing results for Aspergillus fumigatus. Rev Iberoam Micol 2000, 17:107-110.
41. Yu L, Ling G, Deng X, Jin J, Jin Q, Guo N. In Vitro Interaction between fluconazole and triclosan against clinical isolates of fluconazole-Resistant Candida albicans determined by different methods. Antimicrob Agents Chemother 2011, 55:3609-3612. 10.1128/AAC.01313-10, 3122452, 21576450.